Fig. 4From: Clinical investigator perspectives on patient outcomes in children with neuronopathic mucopolysaccharidosis II during intrathecal idursulfase-IT treatmentInvestigators’ rating of disease status/progression based on blinded review of patients from other sites. Orange ratings are from the investigator treating the patient. Blue highlighting indicates blinded ratings the same/similar to the treating investigator. Gray highlighting represents blinded ratings different to the treating investigator. aThis patient transferred from Investigator 4 to Investigator 1; neither conducted a blinded review. NA, not availableBack to article page